Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 2/3 2Phase 3 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Recurrence 4Leukemia 3Burkitt Lymphoma 3Neoplasms 2Lymphoma, T-Cell 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1Leukemia, T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Lymphoid 1Leukemia, Biphenotypic, Acute 1

Interventions

Rituximab 57Cyclophosphamide 56fludarabine 37fludarabine phosphate 31Filgrastim 27Etoposide 22Bortezomib 20Melphalan 19Gemcitabine 19Cytarabine 17Bendamustine Hydrochloride 17Peripheral Blood Stem Cell Transplantation 16Vincristine 15pembrolizumab 14aldesleukin 13Prednisone 13Doxorubicin 12Dexamethasone 12Busulfan 12Whole-Body Irradiation 11Vorinostat 11Tacrolimus 11Sirolimus 11sargramostim 10obinutuzumab 10Lenalidomide 10romidepsin 9Radiotherapy 9Rifampin 8Paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma × pegaspargase × Clear all
NCT00363610 2008-05-20

A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma

Enzon Pharmaceuticals, Inc.

Phase 1 Terminated
19 enrolled
Lymphoid

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡